InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
-0.13%
)
US TECH 100
19,436.00
(
-0.73%
)
Dow Jones
42,313.00
(
0.33%
)
Brent Oil
72.01
(
0.00%
)
Bitcoin
65,712.14
(
-0.25%
)
Post# of 4980016
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NightKilla

Send PM Follow Ignore
Followers 3
Posts 1966
Boards Moderated 0
Alias Born 10/12/2006

NightKilla

Re: NightKilla post# 1732589

Friday, 01/22/2010 10:23:27 AM

Friday, January 22, 2010 10:23:27 AM

Post# of 4980016
CYCC Sapacitabine should be the first drug to hit the market. Currently in preparation for Phase III trials



This drug is believed to have a sales opportunity of over $2 billion annually!!

Exclusive rights in nearly all world territories for CYC682 were acquired from Sankyo by Cyclacel Limited in 2003!!

Sapacitabine received the orphan drug designation from the European Medicines Evaluation Agency (EMEA) for the indications of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in May 2008!!

The orphan drug designation provides for 10 years of market exclusivity in the European Union for sapacitabine, if (when) approved…
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up